A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies
Abstract Background Gastric cancer (GC) ranks fourth in global mortality rates and fifth in prevalence, making it one of the most common cancers worldwide. Recent clinical studies have highlighted the potential of immunotherapies as a promising approach to treating GC. This study aims to shed light...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03655-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585353338290176 |
|---|---|
| author | Reza Panahizadeh Padideh Panahi Vahid Asghariazar Shima Makaremi Ghasem Noorkhajavi Elham Safarzadeh |
| author_facet | Reza Panahizadeh Padideh Panahi Vahid Asghariazar Shima Makaremi Ghasem Noorkhajavi Elham Safarzadeh |
| author_sort | Reza Panahizadeh |
| collection | DOAJ |
| description | Abstract Background Gastric cancer (GC) ranks fourth in global mortality rates and fifth in prevalence, making it one of the most common cancers worldwide. Recent clinical studies have highlighted the potential of immunotherapies as a promising approach to treating GC. This study aims to shed light on the most impactful therapeutic strategies in the context of GC immunotherapy, highlighting both established and emerging approaches. Main body This review examines over 160 clinical studies conducted globally, focusing on the effectiveness of various immunotherapy modalities, including cancer vaccines, adoptive cell therapy, immune checkpoint inhibitors (ICIs), and monoclonal antibodies (mAbs). A comprehensive search of peer-reviewed literature was performed using databases such as Web of Science, PubMed, and Scopus. The selection criteria included peer-reviewed articles published primarily within the last 10 years, with a focus on studies that provided insights into targeted therapies and their mechanisms of action, clinical efficacy, and safety profiles. The findings indicate that these immunotherapy strategies can enhance treatment outcomes for GC, aligning with current treatment guidelines. ICIs like pembrolizumab and nivolumab have shown significant survival benefits in specific GC subgroups. Cancer vaccines and CAR-T cell therapies demonstrate potential, while mAbs targeting HER2 and VEGFR pathways enhance outcomes in combination regimens. We discuss the latest advancements and challenges in targeted therapy and immunotherapy for GC. Given the evolving nature of this field, this research emphasizes significant evidence-based therapies and those currently under evaluation rather than providing an exhaustive overview. Challenges include resistance mechanisms, immunosuppressive tumor environments, and inconsistent results from combination therapies. Biomarker-driven approaches and further research into emerging modalities like CAR-T cells and cancer vaccines are critical for optimizing treatments. Conclusions Immunotherapy is reshaping GC management by improving survival and quality of life. Ongoing research and clinical evaluations are crucial for refining personalized and effective therapies. |
| format | Article |
| id | doaj-art-5ac7d66f20bb485a81ac050377ab5543 |
| institution | Kabale University |
| issn | 1475-2867 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-5ac7d66f20bb485a81ac050377ab55432025-01-26T12:53:30ZengBMCCancer Cell International1475-28672025-01-0125112010.1186/s12935-025-03655-8A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapiesReza Panahizadeh0Padideh Panahi1Vahid Asghariazar2Shima Makaremi3Ghasem Noorkhajavi4Elham Safarzadeh5Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical SciencesStudent Research Committee, Shahid Beheshti University of Medical SciencesCancer Immunology and Immunotherapy Research Center, Ardabil University of Medical SciencesCancer Immunology and Immunotherapy Research Center, Ardabil University of Medical SciencesCancer Immunology and Immunotherapy Research Center, Ardabil University of Medical SciencesCancer Immunology and Immunotherapy Research Center, Ardabil University of Medical SciencesAbstract Background Gastric cancer (GC) ranks fourth in global mortality rates and fifth in prevalence, making it one of the most common cancers worldwide. Recent clinical studies have highlighted the potential of immunotherapies as a promising approach to treating GC. This study aims to shed light on the most impactful therapeutic strategies in the context of GC immunotherapy, highlighting both established and emerging approaches. Main body This review examines over 160 clinical studies conducted globally, focusing on the effectiveness of various immunotherapy modalities, including cancer vaccines, adoptive cell therapy, immune checkpoint inhibitors (ICIs), and monoclonal antibodies (mAbs). A comprehensive search of peer-reviewed literature was performed using databases such as Web of Science, PubMed, and Scopus. The selection criteria included peer-reviewed articles published primarily within the last 10 years, with a focus on studies that provided insights into targeted therapies and their mechanisms of action, clinical efficacy, and safety profiles. The findings indicate that these immunotherapy strategies can enhance treatment outcomes for GC, aligning with current treatment guidelines. ICIs like pembrolizumab and nivolumab have shown significant survival benefits in specific GC subgroups. Cancer vaccines and CAR-T cell therapies demonstrate potential, while mAbs targeting HER2 and VEGFR pathways enhance outcomes in combination regimens. We discuss the latest advancements and challenges in targeted therapy and immunotherapy for GC. Given the evolving nature of this field, this research emphasizes significant evidence-based therapies and those currently under evaluation rather than providing an exhaustive overview. Challenges include resistance mechanisms, immunosuppressive tumor environments, and inconsistent results from combination therapies. Biomarker-driven approaches and further research into emerging modalities like CAR-T cells and cancer vaccines are critical for optimizing treatments. Conclusions Immunotherapy is reshaping GC management by improving survival and quality of life. Ongoing research and clinical evaluations are crucial for refining personalized and effective therapies.https://doi.org/10.1186/s12935-025-03655-8ImmunotherapyMolecular targeted therapyGastric cancerLiterature reviewImmune checkpoint inhibitorsCAR T-cell therapy |
| spellingShingle | Reza Panahizadeh Padideh Panahi Vahid Asghariazar Shima Makaremi Ghasem Noorkhajavi Elham Safarzadeh A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies Cancer Cell International Immunotherapy Molecular targeted therapy Gastric cancer Literature review Immune checkpoint inhibitors CAR T-cell therapy |
| title | A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies |
| title_full | A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies |
| title_fullStr | A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies |
| title_full_unstemmed | A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies |
| title_short | A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies |
| title_sort | literature review of recent advances in gastric cancer treatment exploring the cross talk between targeted therapies |
| topic | Immunotherapy Molecular targeted therapy Gastric cancer Literature review Immune checkpoint inhibitors CAR T-cell therapy |
| url | https://doi.org/10.1186/s12935-025-03655-8 |
| work_keys_str_mv | AT rezapanahizadeh aliteraturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT padidehpanahi aliteraturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT vahidasghariazar aliteraturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT shimamakaremi aliteraturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT ghasemnoorkhajavi aliteraturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT elhamsafarzadeh aliteraturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT rezapanahizadeh literaturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT padidehpanahi literaturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT vahidasghariazar literaturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT shimamakaremi literaturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT ghasemnoorkhajavi literaturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies AT elhamsafarzadeh literaturereviewofrecentadvancesingastriccancertreatmentexploringthecrosstalkbetweentargetedtherapies |